Immune Checkpoint Molecules Expressed on CD4⁺ T Cell Subsets in Chronic Asymptomatic Hepatitis B Virus Carriers With Hepatitis B e Antigen-Negative

Dawei Cui¹,²†, Daixi Jiang³†, Cuilin Yan¹, Xia Liu⁴, Yan Lv², Jue Xie²* and Yu Chen¹*

¹ Department of Laboratory Medicine, The First Affiliated Hospital, Zhejiang University School of Medicine, Key Laboratory of Clinical In Vitro Diagnostic Techniques of Zhejiang Province, Institute of Laboratory Medicine, Zhejiang University, Hangzhou, China, ² Department of Blood Transfusion, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, ³ State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, ⁴ ZJU-Hangzhou Global Scientific and Technological Innovation Center, Hangzhou, China

Background: Chronic hepatitis B virus (HBV) infection remains a major public health problem worldwide. Immune checkpoint molecules expressed on CD4⁺ T cells play critical roles in chronic HBV infection. However, their roles in chronic asymptomatic HBV carriers (ASCs) with hepatitis B e antigen (HBeAg)-negative remain unclear. In this study, we explored the role of immune checkpoint molecules expressed on CD4⁺ T cell subsets in chronic ASCs with HBeAg-negative.

Methods: Human peripheral blood mononuclear cells (PBMCs) from the ASCs with HBeAg-negative and healthy controls (HC) were isolated, and immune checkpoint molecules expressed on CD4⁺ T cell subsets and serum cytokines were detected by flow cytometry. Moreover, the mRNA expressions of immune checkpoint molecules were analyzed by a real-time quantitative PCR assay.

Results: In comparison with HC, CD4⁺ T cells highly expressed LAG-3, TIM-3, and PD-1 in PBMCs from chronic ASCs with HBeAg-negative. Interestingly, the expressions of TIM-3 and PD-1 on circulating follicular helper T (Tfh) cells in ASCs were significantly high. Moreover, high expressions of LAG-3, TIM-3, and PD-1 were different among Treg, Th1, Th2, and Th17 cells. In addition, the expressions of TIM-3 and CTLA-4 mRNA in PBMCs from ASCs were significantly elevated. However, the frequency of CTLA-4⁺CD4⁺ T cell subsets in PBMCs from ASCs was not different from HC. The levels of six cytokines in serum from ASCs were not clearly different from HC.

Conclusion: Immune checkpoint molecules highly expressed on CD4⁺ T cell subsets indicated an important role in chronic ASCs with HBeAg-negative, which provided potential therapeutic targets in the pathogenesis of chronic HBV infection.

Keywords: hepatitis B virus, asymptomatic HBV carriers, CD4⁺ T cells, immune checkpoint molecules, chronic hepatitis B virus
INTRODUCTION

Hepatitis B virus (HBV) infection remains a major health problem in the world, which accounts for roughly one-third of the global population (Yuen et al., 2018; Revill et al., 2019; Iannaccone and Guidotti, 2022). Although only fewer than 5% of adults with HBV infection can develop chronic hepatitis B (CHB), over 250 million individuals with about one million deaths annually are affected with persistent infection, liver cirrhosis, and hepatocellular carcinoma (HCC) worldwide (Trepo et al., 2014; Yuen et al., 2018; Revill et al., 2019). Moreover, the population with hepatitis B e antigen (HBeAg)-negative is dominant with over 85% in the hepatitis B surface antigen (HBsAg)-positive subjects, and more than 350 million are chronic HBV carriers. The chronic HBV carriers with HBSAg-positive and HBeAg-negative can also develop HCC and liver-associated mortality that are related to baseline age, sex, serum HBV-DNA copies, and alanine aminotransferase (ALT) level (Kumar et al., 2009; Trepo et al., 2014; Koffas et al., 2021). Chronic asymptomatic HBV carriers (ASCs) are major individuals (67–80%) among chronic HBV cases, who have normal levels of ALT and low HBV-DNA copies; although they are not treated commonly by drugs, a long-term follow-up for them is necessary (Kumar et al., 2009; Koffas et al., 2021). Although this "inactive" disease phase of the chronic ASCs with HBeAg-negative is closely associated with a favorable prognosis, it is not a truly "inactive" carrier with no obvious liver disease, and the reactivation and the potential risk of disease progression, including HCC and cirrhosis, are not negligible (Kumar et al., 2009; Puoti, 2013; Tang et al., 2018; Koffas et al., 2021). Therefore, these patients can still potentially develop liver disease for persistent HBV infection.

Chronic and persistent HBV infection is a critical causative agent for T-cell dysfunction, including CD4+ T and CD8+ T cells that attenuate or lose the clearance of the virus. The dysfunction of T cells is closely associated with the upregulated immune checkpoint molecules, such as programmed cell death protein-1 (PD-1), lymphocyte activation gene-3 (LAG-3), T-cell immunoglobulin and mucin domain-3 (TIM-3), and cytotoxic T-lymphocyte antigen-4 (CTLA-4) (Bengsch et al., 2014; Park et al., 2016; Salimzadeh et al., 2018; Chen and Tian, 2019; Fisicaro et al., 2020; Ferrando-Martinez et al., 2021). Accumulating evidence indicates that the blockade of immune checkpoint molecules contributes to the restoration of dysfunctional T-cell-mediated adaptive immune responses, which partially promote the clearance of chronic viruses, including HBV, and the remission of the disease (Lang et al., 2019; Jin et al., 2021; Sears et al., 2021). The function of CD8+ T cells can be impaired without the help of CD4+ T cells, and CD8+ T cells contribute to controlling and clearing viruses (Zuniga et al., 2015; Saedi et al., 2018; Sears et al., 2021). Unfortunately, the function of CD4+/CD8+ T cells is dysregulated in CHB infection, which is closely correlated with high expressions of immune checkpoint molecules on them (Bertoletti and Ferrari, 2012; Dong et al., 2019; Buschow and Jansen, 2021). Therefore, the immune checkpoint molecules on specific CD4+ T cell subsets in chronic HBV infection should be further elucidated in the ASCs with HBeAg-negative, which will contribute to a better understanding of CD8+ T cell dysfunction during CHB infection.

In this study, the immune checkpoint molecules (PD-1, TIM-3, LAG-3, and CTLA-4) expressed on specific CD4+ T cell subsets were investigated in peripheral blood mononuclear cells (PBMCs) from chronic ASCs with HBeAg-negative and normal ALT level, and the HBV-specific CD4+ T cell subset-associated cytokines were also detected, which will provide potential therapeutic targets for the development of chronic HBV infection.

MATERIALS AND METHODS

Demographic Characteristics

A total of 22 chronic ASCs with HBeAg-negative and normal ALT levels were enrolled according to the Guideline of Prevention and Treatment for Chronic Hepatitis B (2019 version), and gender- and age-matched 22 healthy controls (HC) were recruited at the First Affiliated Hospital, Zhejiang University School of Medicine (Hangzhou, China) in this study. The individuals were excluded from the study if they have diabetes, autoimmune diseases, hematological system diseases, and other hepatotropic diseases, and the HC were also excluded if they have a vaccine history within 6 months. The ASCs with

| Variables | ASCs (n = 22) | HC (n = 22) | Range of reference |
|-----------|--------------|-------------|--------------------|
| Age (years) | 47.64 ± 11.12 | 43.82 ± 7.24 | 30 - 70 |
| Gender (M/F) | 14/8 | 14/8 | 1:1 |
| HBsAg (IU/mL) | 1891.83 ± 430.27*** | 0.01 ± 0.01 | 0.00 - 0.05 |
| HBeAg (S/CO) | 0.41 ± 0.01 | 0.34 ± 0.01 | < 0.2 |
| Anti-HBc (S/CO) | 7.89 ± 0.08*** | 2.11 ± 0.53 | > 10.00 |
| Anti-HBe (S/CO) | 0.03 ± 0.01*** | 1.50 ± 0.11 | < 10.00 |
| Anti-HBs (IU/L) | 1.45 ± 0.73** | 194.43 ± 61.57 | > 10.00 |
| ALT (IU/L) | 20.14 ± 1.82 | 21.36 ± 2.04 | 9 - 50 |
| AST (IU/L) | 20.77 ± 1.36 | 18.23 ± 1.18 | 15 - 40 |
| HBV-DNA (IU/mL) | < 30 | NA | LOD = 30 |

ASCs, symptomatic HBV carriers; HC, healthy controls; M/F, male/female; HBsAg, hepatitis B virus surface antigen; HBeAg, hepatitis B virus e antigen; ALT, alanine aminotransferase; AST, aspartate transaminase; LOD, limitation of detection; NA, not applicable. ***P < 0.001.

Abbreviations: HBV, hepatitis B virus; ASC, asymptomatic hepatitis B virus carriers; HC, healthy controls; PBMCs, peripheral blood mononuclear cells; Tfh, follicular helper T cells; Treg, regulatory T cells; PD-1, programmed cell death protein-1; TIM-3, T-cell immunoglobulin and mucin domain-3; CTLA-4, cytotoxic T-lymphocyte antigen-4; LAG-3, lymphocyte activation gene-3; IFN-γ, interferon-gamma; TNF-α, tumor necrosis factor-α; CXCR3, C-X-C motif chemokine receptor type 5; Th1, T helper cell type 1; Th2, T helper cell type 2; Th17, T helper cell type 17; HBeAg, hepatitis B e antigen; HCC, hepatocellular carcinoma; ALT, alanine aminotransferase; AST, aspartate aminotransferase; HBsAg, hepatitis B surface antigen; CCR6, C-C motif chemokine receptor 6; CXCR3, C-X-C motif chemokine receptor 3.
chronic HBeAg-negative and normal ALT levels who received HBV treatment within 6 months before blood sampling were also excluded. The clinical and laboratory characteristics of ASCs and HC are presented in Table 1. Written informed consent of all individuals was obtained according to the Declaration of Helsinki (1964) and was approved by the Medical Ethical Committee of the First Affiliated Hospital, Zhejiang University School of Medicine in this study (approval no. 2021-523).

Serological Analysis of Hepatitis B Virus Markers and Liver Function
Serum ALT and AST levels were detected by an automated biochemical analyzer (Roche cobas p 671, Switzerland). The serum HBsAg, anti-HBs, HBeAg, anti-HBe, and anti-HBc levels were tested by a chemiluminescent microparticle immuno Assay (Abbott Alinity i, United States). The serum HBV-DNA titers were determined by an ABI 7500 fluorescent quantitative PCR system (Applied BioSystems, United States).

Isolation of Human Peripheral Blood Mononuclear Cells
Human fresh PBMCs were isolated from fresh whole blood samples of the individuals by density gradient centrifugation using a Ficoll–Hypaque solution (CL5020, Netherlands) according to the manufacturer’s protocol. The isolated PBMCs were washed two times using sterile phosphate-buffered saline (PBS) and transferred into tubes for use in subsequent experiments.

Flow Cytometry Analysis
Human PBMCs were resuspended with 200 µL PBS buffer and incubated with fluorochrome-conjugated antibodies, antihuman Krome Orange-CD4, Alexa Fluor 750-CD45RA, ECD-CD25 (Beckman Coulter Life Science, United States), Pacific blue™-CXCR5, PerCP/Cy5.5-PD-1, APC-TIM-3, Brilliant violet 650™-LAG-3, PE/Cy7-CTLA-4, FITC-CCR6, and PE-CXCR3 (BioLegend, United States), for 20 min at room temperature, and matched isotype controls were performed in this study according to the manufacturer’s instructions. The samples were detected by the CytoFLEX Flow Cytometer, and the data were analyzed by CyExpert software (Beckman Coulter, United States).

Quantitative Real-Time Polymerase Chain Reaction
Total RNA was extracted from fresh PBMCs by the RNeasy Mini Kit (Qiagen, Germany), which was used to synthesize cDNA by a reverse transcription reagent kit (Takara, China). Real-time quantitative PCR was used to detect the expression levels of target genes in triplicate by Takara SYBR Mini Kit (Takara, China) by ABI QuantStudio 5 (Applied Biosystems, United States) as previously described (Shen et al., 2020). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control in this study. The sequences of the specific primers are listed as follows: PD-1 forward 5′-AAGGCCGAGATCAAGAGAGGC-3′ and reverse 5′-CAACCCACAGGTTTGGAACCTG-3′; TIM-3 forward 5′-GACTCTGACAGATGGGATC-3′ and reverse 5′-GATGGAAGCTTCTCGAGCTGTC-3′; LAG-3 forward 5′-GCAATGTACTACAGAGCTGTC-3′ and reverse 5′-AGGAAAGCTCAGTCTCAG-3′; CTLA-4 forward 5′-ACGGACTCTACTCATCTGCAAAG-3′ and reverse 5′-GGAGGAAGTCAGATCTGGCA-3′; and GAPDH forward 5′-GTTCCTCTGACCTTAAACGGC-3′ and reverse 5′-ACCACCTGTGTCTGTTAGCCAA-3′.

Serological Detection of Cytokines
The serum levels of IFN-γ, IL-2, IL-4, IL-6, IL-10, and TNF-α were tested by the flow fluorescence immune microbeads assay (C Belgene, China) according to the manufacturer’s protocol. In brief, 25 µL fluorescence detection reagent and 25 µL immune microbeads were added to 25 µL serum samples, and the mixed solutions were darkly incubated for 2.5 h at room temperature. Then, they were washed and resuspended with 100 µL PBS buffer, and cytokines were detected by BD FACSCanto II (BD, United States).

Statistical Analysis
Statistical analysis of the experimental data was performed using the Mann–Whitney U test or a one-way ANOVA using GraphPad Prism 7 software (GraphPad Software, Inc., CA). The differences were determined between two unpaired groups by Student’s t-test, and significant differences were determined by paired t-tests between the two paired groups. Spearman’s correlation coefficients were used to analyze correlations of different variables between the two groups. All P-values < 0.05 were considered to be statistically different.

RESULTS
Expanded Immune Checkpoint Molecules Expressed on CD4⁺ T Cells in Chronic Asymptomatic Hepatitis B Virus Carriers With Hepatitis B e Antigen-Negative
In this study, there was a significant difference in baseline characteristics, including HBsAg, anti-HBc, anti-HBe, and anti-HBs levels from the patients’ chronic ASCs with HBeAg-negative; however, no significant difference was found in ALT and AST levels between 22 chronic ASCs with HBeAg-negative and 22 healthy controls (HC) (Table 1). Previous reports indicated that circulating CD4⁺ T cells with immune checkpoint molecules played a critical role in chronic HBV infection, but the related studies about chronic ASCs were few (Ye et al., 2015; Dong et al., 2019). The frequencies of circulating CD4⁺ T cells with four immune checkpoint molecules, including TIM-3, LAG-3, CTLA-4, and PD-1, were detected between chronic ASCs with HBeAg-negative and HC by flow cytometry (Figure 1A). Compared with HC, the frequency of circulating TIM-3⁺CD4⁺ T cells, LAG-3⁺CD4⁺ T
cells, and PD-1+CD4+ T cells was significantly elevated in ASCs (Figures 1B,C,E, respectively). However, the frequency of CTLA-4+CD4+ T cells was not significantly different between chronic ASCs with HBeAg-negative and HC (Figure 1D). In addition, there was no significant correlation between immune checkpoint molecules expressed on CD4+ T cells
FIGURE 2 | Immune checkpoint molecules expressed on CXCR5+CD45RA−CD4+ Tfh cells. (A) Flow cytometry detection of PD-1+, TIM-3+, LAG-3+, and CTLA-4+ on CXCR5+CD45RA−CD4+ Tfh cells and CXCR5−CD45RA−CD4+ Th cells in ASCs and HC. (B–E) Analysis of the expression of PD-1+, TIM-3+, LAG-3+, and CTLA-4+ on CXCR5+CD45RA−CD4+ Tfh cells and CXCR5−CD45RA−CD4+ Th cells in ASCs and HC. Data represent the mean± SD. **P < 0.01, ***P < 0.001.
and serum HBsAg levels from chronic ASCs with HBeAg-negative (Table 2).

**Immune Checkpoint Molecules Expressed on Tfh Cells in Chronic Asymptomatic Hepatitis B Virus Carriers With Hepatitis B e Antigen-Negative**

Accumulated evidence showed the critical role of follicular helper T (Tfh) cells with high expressions of immune checkpoint molecules including TIM-3 and PD-1 in viral infection, including chronic HBV infection (Ye et al., 2015; Vella et al., 2017; Zhuo et al., 2020; Granito et al., 2021). In this study, effector CD45RA− (Andrews et al., 2019; Schnell et al., 2020; Granito et al., 2021) Tfh cells and immune checkpoint molecules were detected by flow cytometry (Figure 2A). The frequency of circulating CD4+ T cells with immune checkpoint molecules was detected between chronic ASCs with HBeAg-negative and HC by flow cytometry (Figure 2A). Compared with HC, the frequency of circulating TIM-3+CD45RA−CXCR5+CD4+ Tfh cells and PD-1+CD45RA−CXCR5+CD4+ Tfh cells was notably increased, which also was higher than that of TIM-3+CD45RA−CXCR5−CD4+ T cells and PD-1+CD45RA−CXCR5−CD4+ T cells in ASCs (Figures 2B,E). However, there was no significant difference in the frequency of LAG-3+CD45RA−CXCR5+CD4+ Tfh cells, TIM-3+CD45RA−CXCR5−CD4+ T cells, and PD-1+CD45RA−CXCR5−CD4+ T cells between chronic ASCs with HBeAg-negative and HC (Figures 2B–E). In addition, there was no significant correlation between immune checkpoint molecules expressed on Tfh cells and serum HBsAg levels from chronic ASCs with HBeAg-negative (Table 2).

**Immune Checkpoint Molecules Expressed on Treg Cells**

Previous reports indicated that Treg cells with high expressions of immune checkpoint molecules played an essential role in cancer types, autoimmune diseases, and viral infections (Andrews et al., 2019; Schnell et al., 2020; Granito et al., 2021). In this study, CD45RA−CD25+CXCR5−CD4+ Treg cells with immune checkpoint molecules were detected by flow cytometry (Figure 3A). In comparison with that of HC, the frequency of CD45RA−CD25+CXCR5−CD4+ Treg cells with TIM-3 or PD-1 and the frequency of LAG-3+CD45RA−CD25+CXCR5−CD4+ Treg cells in chronic ASCs with HBeAg-negative were significantly high (Figures 3B,C,E). Moreover, similar significant results were found for the frequency of CD45RA−CD25−CXCR5−CD4+ T cells with TIM-3 or PD-1 (Figures 3B,E). However, there was no significant difference in the frequency of CTLA-4+CD45RA−CD25+CXCR5−CD4+ Treg cells between chronic ASCs with HBeAg-negative and HC (Figure 3D). In addition, there was no significant correlation between immune checkpoint molecules expressed on Treg cells and serum HBsAg levels from chronic ASCs with HBeAg-negative (Table 2).

**Immune Checkpoint Molecules Expressed on Other CD4+ T Cell Subsets in Chronic Asymptomatic Hepatitis B Virus Carriers With Hepatitis B e Antigen-Negative**

Previous studies showed that human Th1 (CXCR3+CCR6−), Th2 (CXCR3−CCR6−), and Th17 (CXCR3−CCR6+) cells from PBMCs were distinguished based on the expressions of chemokine receptors CXCR3 and CCR6 on CD4+ T cells (Maccker et al., 2012; Kubo et al., 2017). In this study, to further investigate the frequency of immune checkpoint molecules expressed on other CD4+ T cell subsets in chronic ASCs with HBeAg-negative and HC, flow cytometry was used to detect these immune checkpoint molecules, and human Th1 (CXCR3+CCR6−), Th2 (CXCR3−CCR6−), and Th17 (CXCR3−CCR6+) cells were also defined by gating CD45RA−CXCR5−CD4+ T cells from PBMCs of ASCs and HC (Figure 4A). The results showed that the frequency of TIM-3+Th1 cells, TIM-3+Th2 cells, LAG-3+Th17 cells, PD-1+Th2 cells, and PD-1+Th17 cells was significantly increased; however, the frequency of TIM-3+Th17 cells, LAG-3+Th1 cells, LAG-3+Th2 cells, CTLA-4+Th1/2/17 cells, and PD-1+Th1 cells was not varied considerably in chronic ASCs with HBeAg-negative in comparison with HC (Figures 4B–E). Interestingly, Th1 cells highly expressed TIM-3, CTLA-4, and PD-1 compared with TH2 and Th17 cells (Figures 4B,E). Th1 and Th17 cells were highly expressed LAG-3 compared with Th2 cells in chronic ASCs with HBeAg-negative (Figures 4B,C). In addition, there was no significant correlation between immune checkpoint molecules expressed on Th1, Th2, and Th17 cells and serum HBsAg levels from chronic ASCs with HBeAg-negative (Table 2).

**Immune Checkpoint Molecules mRNA Expression in Chronic Asymptomatic Hepatitis B Virus Carriers With Hepatitis B e Antigen-Negative**

To further explore the mRNA levels of PD-1, TIM-3, LAG-3, and CTLA-4, the total RNA in PBMCs isolated from ASCs and HC was used to assess the expression levels of the four molecules by PCR method. The results displayed that the relative mRNA levels of TIM-3 and CTLA-4 genes were notably increased in the PBMCs from the ASCs in comparison with those from the HC (Figures 5A,D), but PD-1 and LAG-3 mRNA levels were not notably different between the ASCs and HC (Figures 5B,C).

**Serum Levels of Cytokines in Chronic Asymptomatic Hepatitis B Virus Carriers With Hepatitis B e Antigen-Negative**

To further investigate the immune status of ASCs with negative HBeAg, serum levels of some important cytokines were tested by flow cytometry. The results showed that decreased levels of serum IL-2, IL-4, and TNF-α were not notably different in chronic ASCs with negative HBeAg in comparison with HC (Figures 6A,B,E). Serum IL-6, IL-10, and IFN-γ levels were not significantly
changed in chronic ASCs with HBeAg-negative in comparison with HC (Figures 6C,D,F). However, there was no correlation between these cytokine levels and HBSAg concentrations in chronic ASCs with HBeAg-negative (data not shown).

**DISCUSSION**

In this study, we provided an insight into the immune checkpoint molecules expressed on circulating human CD4+ T cell subsets from chronic ASCs with HBeAg-negative. The results showed that immune checkpoint molecules (TIM-3, LAG-3, and PD-1) expressed on CD4+ T cells were significantly upregulated in PBMCs from chronic ASCs with HBeAg-negative. Interestingly, a comprehensive analysis displayed a high frequency of circulating TIM-3+ or PD-1+ Tfh cells in chronic ASCs with HBeAg-negative. Moreover, increased expressions of TIM-3, LAG-3, and PD-1 molecules on Th1, Th2, Th17, and Treg cells and TIM-3 and CTLA-4 mRNA levels in PBMCs from chronic ASCs with HBeAg-negative in comparison with HC were notably different. The chronic ASCs with HBeAg-negative can still develop into the stage of CHB with HBeAg-positive and end-stage liver disease including HCC and liver fibrosis (Kumar et al., 2009; Puoti, 2013; Tang et al., 2018; Koffas et al., 2021).

Previous reports have shown that the co-inhibitory molecules on T cells contributed to the development of pathogenesis in patients with chronic HBV infection (Salimzadeh et al., 2018; Lang et al., 2019; Jin et al., 2021; Sears et al., 2021). Taken
FIGURE 4 | CD4+ T cell subsets showed different levels of immune checkpoint molecules. (A) Analysis of CD4+ T cell subsets. (B) TIM-3+ expression on Th1, Th2, and Th17 cells. (C) LAG-3+ expression on Th1, Th2, and Th17 cells. (D) CTLA-4+ cells expressed on Th1, Th2, and Th17 cells. (E) PD-1+ expression on Th1, Th2, and Th17 cells. Data represent the mean ± SD. **P < 0.01; ***P < 0.001.

together, these findings indicated that elevated expressions of immune checkpoint molecules (TIM-3, LAG-3, and PD-1) on CD4+ T cell subsets might play a critical role in chronic ASCs with HBeAg-negative.

CD4+ T cell dysfunction in chronic HBV infection affected the function of other immune cells, including HBV-specific CD8+ T cells and B cells, and resulted in disruption of the host’s immune responses and persistent HBV infection (Trepo et al., 2014; Yuen et al., 2018; Revill et al., 2019; Iannaccone and Guidotti, 2022). Dysfunctional CD4+ T cells are closely correlated with the upregulation of immune co-inhibitory molecules expressed on CD4+ T cells that usually played an immunosuppressive function, such as TIM-3, PD-1, LAG-3, and CTLA-4 (Park et al., 2016; Salimzadeh et al., 2018; Dong et al., 2019; Fisicaro et al., 2020; Ferrando-Martinez et al., 2021). Previous reports showed an increased frequency of PD-1+CD4+ T cells, TIM-3+CD4+ T cells, LAG-3+CD4+ T cells, and CTLA-4+CD4+ T cells in chronic HBV infection, and the blockade of the co-inhibitory receptors contributed to the restoration of CD4+ T cell proliferation and function and promoted cytotoxic effector of CD8+ T cells that played critical roles in viral clearance and disease pathogenesis of sustained HBV infection (Peng et al., 2008; Dong et al., 2017, 2019; Buschow and Jansen, 2021; Xiong et al., 2021). However, these studies did not display detailed data on ASCs of patients with chronic HBV. Our results showed an expanded frequency of PD-1+CD4+ T cells, TIM-3+CD4+ T
cells, and LAG-3$^+$CD4$^+$ T cells, but not CTLA-4$^+$CD4$^+$ T cells in chronic ASCs with HBeAg-negative in comparison with HC. The number and status of the patients possibly affected the statistical analysis of CTLA-4$^+$CD4$^+$ T cell frequencies in this study. In addition, the mRNA levels of TIM-3 and CTLA-4 expressions, but not PD-1 and LAG-3 mRNA, were notably
in chronic ASCs with HBeAg-negative in comparison with HC, which were not completely consistent with previous reports (Yu et al., 2009; Zhang et al., 2014; Cheng et al., 2021; Liu et al., 2021). The discrepancy may be associated with the number and the status of the special population who are the “inactive carrier” phase of chronic HBV infection, and these co-inhibitory receptors are also expressed in other immune cells, including CD8+ T cells, innate lymphoid cells (ILCs), and NK cells (Kumar et al., 2009; Puoti, 2013; Riva and Chokshi, 2018; Tang et al., 2018; Mariotti et al., 2019; Fiscarco et al., 2020; Koffas et al., 2021; Mak et al., 2021).

Accumulating evidence indicates that high expressions of immune checkpoint molecules (TIM-3, PD-1, CTLA-4, and LAG-3) on CD4+ T cells are related to decreased secretion of cytokines and proliferation capacity of T cells, such as IFN-γ + Th1, IL-4+Th2, IL-17A+Th17, and IL-21+Th17 cells, except for PD-1high Th cells that have the capacity of inducing B-cell response and the generation of specific antibodies against antigens or viruses (Gibney et al., 2016; Park et al., 2016; Saeidi et al., 2018; Buschow and Jansen, 2021). However, Treg cells with increased expressions of immune checkpoint molecules displayed a high immunosuppressive function on HBV-specific Th1 and Tfh responses and promoted IL-10 and TGF-B1 secretion (Stoop et al., 2005; Buschow and Jansen, 2021). This study showed that the frequencies of circulating TIM-3+ or PD-1+ TTh cells and TIM-3, LAG-3, and PD-1 molecules on Th1, Th2, Th17, and Treg cells were significantly expanded in chronic ASCs with HBeAg-negative in comparison with HC, which were partially accordant with previous reports (Stoop et al., 2005; Wang R. et al., 2018; Wang X. et al., 2018). These findings implied that chronic HBV infection resulted in the host’s immune disorder and dysregulation by upregulating immune checkpoint molecules, including TIM-3, PD-1, CTLA-4, and LAG-3 on T cells, that induced T-cell dysfunction in chronic HBV infection. In addition, our results showed that serum cytokines (IL-2, IL-4, and TNF-a) had a low trend in chronic ASCs with HBeAg-negative in comparison with HC, which were partially consistent with previous reports (Ayada et al., 2006; Wang X. et al., 2018; Zhong et al., 2021). These cytokines play a critical role in regulating CD4/CD8+T cell proliferation and differentiation and the production of various specific antibodies to control persistent HBV infection (Buschow and Jansen, 2021; Mak et al., 2021; Zhong et al., 2021).

Our study showed some interesting results, including four important immune checkpoint molecules expressed on CD4+ T cells and their subsets in chronic ASCs with HBeAg-negative. However, several limitations are listed in the following. First, the sample size was relatively small. Second, the function of these CD4+ T cells and their subsets with high expressions of the immune checkpoint molecules should be explored by a large number of samples in further study. The function of the co-inhibitory molecules on CD4+ T cells includes the cellular metabolism, cytokines secretion, differentiation, and helper capacity for CD8+T cells and B cells, which will be precisely explored by multi-omics methods.

CONCLUSION

In summary, during chronic ASCs with HBeAg-negative infection, CD4+ T cells and their subsets, including Th1, Th2, Th17, Tf, and Treg cells, showed high expressions of immune checkpoint molecules (TIM-3, PD-1, CTLA-4, and LAG-3) and decreased the secretion of cytokines. Currently, immune checkpoint-based therapies were used in many diseases, including cancer types, autoimmune diseases, and viral infections, which showed satisfactory curative effects for patients and animals. Taken together, immune checkpoint-based therapies have potential values for chronic ASCs with HBeAg-negative. These findings could provide potential therapeutic implications for chronic HBV infection by regulating CD4+ T cell’s functional therapy.

DATA AVAILABILITY STATEMENT

The original contributions presented in the article, further inquiries can be directed to the corresponding author/s.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by the Medical Ethical Committee of the First Affiliated Hospital, Zhejiang University School of Medicine (Approval No. 2021-523). The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

DC wrote the manuscript. DC and DJ performed the experiments and analyzed the data. DC, DJ, CY, and YL collected the clinical data and samples. DC, DJ, and XL revised the manuscript. DC, YC, and JX conceived the topic and revised the manuscript. All authors approved the submitted version.

FUNDING

This work was supported by the National Natural Science Foundation of China (Grant Nos. 81871709, 91846103, 81971994, and 82172335), the Zhejiang Provincial Key Research and Development Program (No. 2020C03032), and the Zhejiang Provincial Natural Science Foundation of China (No. LQ20H080002).

ACKNOWLEDGMENTS

We gratefully appreciate the highly qualified native English-speaking editors at American Journal Experts (AJE) for providing a reputable English language editing service for our manuscript.
REFERENCES

Andrews, L. P., Yano, H., and Vignali, D. A. A. (2019). Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backslides. Nat. Immunol. 20, 1425–1434. doi: 10.1038/s41590-019-0512-0

Ayada, M., Ishikawa, T., Okumura, A., Tanabe, J., Ito, H., Ohashi, T., et al. (2006). Alteration of serum cytokine balances among different phases of chronic hepatitis B virus infection. Hepatol. Res. 34, 214–221. doi: 10.1016/j.hepre.2006.01.001

Bengsch, B., Martin, B., and Thimme, R. (2014). Restoration of HBV-specific CD8+ T cell function by PD-1 blockade in inactive carrier patients is linked to T cell differentiation. J. Hepatol. 61, 1212–1219. doi: 10.1016/j.jhep.2014.07.005

Bertoletti, A., and Ferrari, C. (2012). Innate and adaptive immune responses in hepatitis B virus-related liver diseases. Lab. Med. 52, 439–451. doi: 10.1093/labmed/lmaa10

Bui, Y., Hu, X., Hu, Y., Yu, L., Ji, H., Li, W., et al. (2022). T follicular helper cells improve the response of patients with chronic hepatitis B to interferon by promoting HBsAb production. J. Gastroenterol. 57, 30–45. doi: 10.1007/s00357-021-01840-w

Maecker, H. T., McCoy, J. P., and Nussenblatt, R. (2012). Standardizing immunophenotyping for the Human Immunology Project. Nat. Rev. Immunol. 12, 191–200. doi: 10.1038/nri3158

Mak, L. Y., Seto, W. K., and Yuen, M. F. (2021). Novel antivirals in clinical development for chronic hepatitis B infection. Viruses 13:1169. doi: 10.3390/v13061169

Mariotti, F. R., Quatrini, L., Munari, E., Vacca, P., and Moretta, L. (2019). Innate lymphoid cells: expression of PD-1 and other checkpoints in normal and pathological conditions. Front. Immunol. 10:1010. doi: 10.3389/fimmu.2019.00910

Park, J. J., Wong, D. K., Wahed, A. S., Lee, W. M., Feld, J. J., Terrault, N., et al. (2016). Hepatitis B virus-specific and global T-cell dysfunction in chronic hepatitis B. Gastroenterology 150, 684–935.e. doi: 10.1053/j.gastro.2015.11.050

Peng, G., Li, S., Wu, W., Sun, Z., Chen, Y., and Chen, Z. (2008). Circulating CD4+CD25+ regulatory T cells correlate with chronic hepatitis B infection. Immunology 123, 57–65. doi: 10.1111/j.1365-2567.2007.02691.x

Puoti, C. (2013). How to manage HBsAg-negative chronic HBV infection with normal alanine aminotransferase levels in clinical practice? Eur. J. Intern. Med. 24, 100–103. doi: 10.1016/j.ejim.2012.10.013

Reilv, P. A., Chisari, F. V., Block, J. M., Dandri, M., Gehring, A. J., Guo, H., et al. (2019). A global scientific strategy to cure hepatitis B. Lancet Gastroenterol. Hepatol. 4, 545–558. doi: 10.1016/S2468-1253(19)30119-0

Riva, A., and Chokshi, S. (2018). Immune checkpoint receptors: homeostatic regulators of immunity. Hepatol. Int. 12, 223–236. doi: 10.1007/s12072-018-9867-9

Saeidi, A., Zandi, K., Cheok, Y. Y., Saedii, H., Wong, W. F., Lee, C. Y. Q., et al. (2018). T cell exhaustion in chronic infections: reversing the state of exhaustion and reinvigorating optimal protective immune responses. Front. Immunol. 9:2569. doi: 10.3389/fimmu.2018.02569

Salmizadeh, L., Le Bert, N., Dutertre, C. A., Gill, U. S., Newell, E. W., Frey, C., et al. (2018). PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. J. Clin. Invest. 128, 4573–4587. doi: 10.1172/JCI121857

Schnell, A., Bod, L., Madi, A., and Kuchroo, V. K. (2020). The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity. Cell Res. 30, 285–299. doi: 10.1038/s41422-020-0277-x

Sears, J. D., Waldron, K. J., Wei, J., and Chang, C. H. (2017). Targeting metabolism to reverse T-cell exhaustion in chronic viral infections. Immunology 162, 135–144. doi: 10.1111/imm.13238

Shen, W., Ye, H., Zhang, X., Huo, L., Shen, J., Zhu, L., et al. (2020). Elevated regulatory B cells. Nat. Rev. Immunol. 20:27. doi: 10.1038/s41577-020-01885-3

Stoop, J. N., van der Molen, R. G., Baan, C. C., van der Laan, L. J., Kuipers, E. J., Kusters, J. G., et al. (2005). Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 41, 771–778. doi: 10.1002/hep.20649

Tang, L. S. Y., Covert, E., Wilson, E., and Kottlák, S. (2018). Chronic hepatitis B infection: a review. JAMA 319, 1802–1813. doi: 10.1001/jama.2018.3795

Trepo, C., Chan, H. L., and Lok, A. (2014). Hepatitis B virus infection. Lancet 384, 2053–2063. doi: 10.1016/S0140-6736(14)60220-8

Vella, L. A., Herati, R. S., and Wherry, E. J. (2017). CD4+CD25+ regulatory T cells differentiate in chronic viral infections: The Th9 perspective. Trends Mol. Med. 23, 1072–1087. doi: 10.1016/j.molmed.2017.10.001

Wang, R., Xie, R., and Song, Z. (2018). Circulating regulatory T cells are enriched in patients with chronic hepatitis B infection and induce the differentiation of regulatory B cells. Exp. Cell Res. 365, 171–176. doi: 10.1016/j.yexcr.2018.02.031
Wang, X., Dong, Q., Li, Q., Li, Y., Zhao, D., Sun, J., et al. (2018). Dysregulated response of follicular helper T cells to hepatitis B surface antigen promotes HBV persistence in mice and associates with outcomes of patients. *Gastroenterology* 154, 2222–2236. doi: 10.1053/j.gastro.2018.03.021

Xiong, S., Zhu, D., Liang, B., Li, M., Pan, W., He, J., et al. (2021). Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers associated with HBsAg loss. *EBioMedicine* 69:103464. doi: 10.1016/j.ebiom.2021.103464

Yan, L., Cai, B., Li, Y., Wang, M. J., An, Y. F., Deng, R., et al. (2020). Dynamics of NK, CD8 and Th cell mediated the production of cytokines and antiviral antibodies in Chinese patients with moderate COVID-19. *J. Cell Mol. Med.* 24, 14270–14279. doi: 10.1111/jcmm.16044

Ye, B., Liu, X., Li, X., Kong, H., Tian, L., and Chen, Y. (2015). T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. *Cell Death Dis.* 6:e1694. doi: 10.1038/cddis.2015.42

Yu, Y., Wu, H., Tang, Z., and Zang, G. (2009). CTLA4 silencing with siRNA promotes deviation of Th1/Th2 in chronic hepatitis B patients. *Cell Mol. Immunol.* 6, 123–127. doi: 10.1038/cmi.2009.17

Yuen, M. F., Chen, D. S., Dusheiko, G. M., Janssen, H. L. A., Lau, D. T. Y., Locarnini, S. A., et al. (2018). Hepatitis B virus infection. *Nat. Rev. Dis. Primers* 4:18035. doi: 10.1038/nrdp.2018.35

Zhang, G., Li, N., Zhang, F., Li, F., Yang, C., Zhu, Q., et al. (2014). PD-1 mRNA expression is associated with clinical and viral profile and PD1 3’-untranslated region polymorphism in patients with chronic HBV infection. *Immunol. Lett.* 162(1 Pt A), 212–216. doi: 10.1016/j.imlet.2014.09.001

Zhong, S., Zhang, T., Tang, L., and Li, Y. (2021). Cytokines and chemokines in HBV infection. *Front. Mol. Biosci.* 8:805625. doi: 10.3389/fmolb.2021.805625

Zhuo, Y., Zhang, Y. F., Wu, H. J., Qin, L., Wang, Y. P., Liu, A. M., et al. (2017). Interaction between Galectin-9/TIM-3 pathway and follicular helper CD4(+) T cells contributes to viral persistence in chronic hepatitis C. *Biomed. Pharmacother.* 94, 386–393. doi: 10.1016/j.biopharm.2017.07.134

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Cui, Jiang, Yan, Liu, Lv, Xie and Chen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.